transplantologiyaТрансплантологияTransplantologiya. The Russian Journal of Transplantation2074-05062542-0909IPO Association of Transplantologists10.23873/2074-0506-2009-0-1-13-19transplantologiya-234Research ArticleОБЗОРНЫЕ СТАТЬИ И ЛЕКЦИИREVIEW ARTICLES AND LECTURESМетодика формирования и ведения «листа ожидания» трансплантации печениProcedure for drawing up and keeping a liver transplantation waiting listХубутияМ. Ш.KhubutiaM. Sh.

Кафедра трансплантологии и искусственных органов

Department of Transplantology and Artificial Organs

АндрейцеваО. И.AndreitsevaO. I.

Кафедра трансплантологии и искусственных органов

Ольга Ивановна Андрейцева 

Department of Transplantology and Artificial Organs

olga-ltc@rambler.ruЖуравельС. В.ZhuravelS. V.

Кафедра трансплантологии и искусственных органов

Department of Transplantology and Artificial Organs

ГуляевВ. А.GulyaevV. A.

Кафедра трансплантологии и искусственных органов

Department of Transplantology and Artificial Organs

СалиенкоА. А.SaliyenkoA. A.

Кафедра трансплантологии и искусственных органов

Department of Transplantology and Artificial Organs

ЧжаоА. В.ChzhaoA. V.

Кафедра трансплантологии и искусственных органов

Department of Transplantology and Artificial Organs

МГСМУРоссияMoscow State Medical University of DentistryRussian Federation200916082018011319Copyright © Хубутия М.Ш., Андрейцева О.И., Журавель С.В., Гуляев В.А., Салиенко А.А., Чжао А.В., 20182018Хубутия М.Ш., Андрейцева О.И., Журавель С.В., Гуляев В.А., Салиенко А.А., Чжао А.В.Khubutia M.S., Andreitseva O.I., Zhuravel S.V., Gulyaev V.A., Saliyenko A.A., Chzhao A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.jtransplantologiya.ru/jour/article/view/234

Представлен опыт формирования Листа ожидания трансплантации печени в НИИ СП им. Н.В. Склифосовского. Международные рекомендации, касающиеся обследования реципиентов, оценки степени тяжести терминального заболевания печени, класса неотложности выполнения операции даны с учетом опыта ведения 324 пациентов с различными заболеваниями печени. Проанализирована структура Листа ожидания по этиологии заболевания, подчеркнута необходимость динамической оценки степени тяжести реципиента, а также профилактики и лечения вирусных заболеваний в перитрансплантационном периоде.

Experience of Institute of Emergency Medicine n.a. Sklifosovski in management of liver transplantation waiting list is analyzed. International protocols are described and applied to the treatment of 324 pts. with end stage liver diseases. Authors stressed the importance of dynamic evaluation of severity of liver disease as well as treatment of different complications such as resistant ascites, esophageal varicose, encephalopathy and gastrointestinal bleeding. Prophylactics and treatment of viral hepatitis takes important place in the management of liver transplant recipient pts.

«лист ожидания»трансплантация печениобследование реципиентовпоказания к трансплантацииa waiting listliver transplantationexaminations of recipientsindications for transplantationReferencesNational Organ Transplant Act of 1984 (NOTA). 42 USC §274.National Organ Transplant Act of 1984 (NOTA). 42 USC §274.Rosen H.R., Shackleton C.R., Martin P. Indications for and timing of liver transplantation. Med Clin North Am 1996;80:1069—102.Rosen H.R., Shackleton C.R., Martin P. Indications for and timing of liver transplantation. Med Clin North Am 1996;80:1069—102.Martin P. Hepatocellular carcinoma: risk factors and natural history. Liver Transplantаnt Surgery 1998;4(suppl)1998;87—91.Martin P. Hepatocellular carcinoma: risk factors and natural history. Liver Transplantаnt Surgery 1998;4(suppl)1998;87—91.Barbara L., Benzi G., Gaiani S. et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: А multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology 1992;16:132—7.Barbara L., Benzi G., Gaiani S. et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: А multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology 1992;16:132—7.Sheu J.C., Sung J.L., Chen D.S. et al. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 1985;89:259—66.Sheu J.C., Sung J.L., Chen D.S. et al. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 1985;89:259—66.Carithers R.L.Jr. Liver transplantation. Liver Transplаnt Surgery 1999;6:122—35.Carithers R.L.Jr. Liver transplantation. Liver Transplаnt Surgery 1999;6:122—35.Lucey M.R., Brown K.A., Everson G.T. et al. Minimal criteria for placement of adults on the liver transplant waiting list: A report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transplаnt Surgery 1997;3:628—37.Lucey M.R., Brown K.A., Everson G.T. et al. Minimal criteria for placement of adults on the liver transplant waiting list: A report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transplаnt Surgery 1997;3:628—37.Krowka M.J., Porayko M.K., Plevak D.J. et al. Hepatopulmonary syndrome with progressive hypoxemia as an indication for liver transplantation: Case reports and literature review. Mayo Clinic Proceedings 1997;72:44—53.Krowka M.J., Porayko M.K., Plevak D.J. et al. Hepatopulmonary syndrome with progressive hypoxemia as an indication for liver transplantation: Case reports and literature review. Mayo Clinic Proceedings 1997;72:44—53.Sherman M., Peltekian K.M., Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: Incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995;22:432—38.Sherman M., Peltekian K.M., Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: Incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995;22:432—38.Miller W.J., Federle M.P., Campbell W.L. Diagnosis and staging of hepatocellular carcinoma: comparison of CT and sonography in 36 liver transplantation patients. Am J Roentgenol 1991;157:303—6.Miller W.J., Federle M.P., Campbell W.L. Diagnosis and staging of hepatocellular carcinoma: comparison of CT and sonography in 36 liver transplantation patients. Am J Roentgenol 1991;157:303—6.Oka H., Tamori A., Kuroki T. et al. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994;19:61—6.Oka H., Tamori A., Kuroki T. et al. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994;19:61—6.Sherman M., Peltekian K.M., Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: Incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995;22:432—8.Sherman M., Peltekian K.M., Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: Incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995;22:432—8.Isobe H., Imari Y., Sakai H. et al. Subcutaneous seeding of hepatocellular carcinoma following fine-needle aspiration biopsy. J Clin Gastroenterol 1993;17:350—2.Isobe H., Imari Y., Sakai H. et al. Subcutaneous seeding of hepatocellular carcinoma following fine-needle aspiration biopsy. J Clin Gastroenterol 1993;17:350—2.Runyon B.A., Antillon M.R., Akriviadis E.A. et al. Bedside inoculation of blood culture bottles with ascitic fluid is superior to delayed inoculation in the detection of spontaneous bacterial peritonitis. J Clin Microbiol 1990;28:2811—2.Runyon B.A., Antillon M.R., Akriviadis E.A. et al. Bedside inoculation of blood culture bottles with ascitic fluid is superior to delayed inoculation in the detection of spontaneous bacterial peritonitis. J Clin Microbiol 1990;28:2811—2.Anonymous. Organ Procurement and Transplantation Network—HRSA. Final rule with comment period. Fed Register 1998;63:16296—338.Anonymous. Organ Procurement and Transplantation Network—HRSA. Final rule with comment period. Fed Register 1998;63:16296—338.Malinchoc M., Kamath Р.Q., Gordon F.D. et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosys-temic shunts. Hepatology 2000;31:864.Malinchoc M., Kamath Р.Q., Gordon F.D. et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosys-temic shunts. Hepatology 2000;31:864.Kamath P.S., Wiesner R.H., Malmchoc M. et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464.Kamath P.S., Wiesner R.H., Malmchoc M. et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464.Brown R.S., Kumar K.S., Russo M.W. et al. Model for end-stage liver disease and GhildTurcotte-Pugh score as predictors of pretransplant disease severity, posttransplantation outcome, and resource utilization in United Network for Organ Sharing status 2A patients. Liver Transplant 2002;8:278.Brown R.S., Kumar K.S., Russo M.W. et al. Model for end-stage liver disease and GhildTurcotte-Pugh score as predictors of pretransplant disease severity, posttransplantation outcome, and resource utilization in United Network for Organ Sharing status 2A patients. Liver Transplant 2002;8:278.Desaj N.M., Mange K.C., Crawford M.D. et al. Predicting outcome after liver transplantation of newly derived transplantation: utility of the MODEL FOR END-STAGE LIVER DISEASE and a discrimination function. Transplantation 2004;77:99—106.Desaj N.M., Mange K.C., Crawford M.D. et al. Predicting outcome after liver transplantation of newly derived transplantation: utility of the MODEL FOR END-STAGE LIVER DISEASE and a discrimination function. Transplantation 2004;77:99—106.Showstack J., Katz P.P., Lake J.R. et al. Resource utilization in liver transplantation: offects of patient characteristics and clinical practice. NIDDK Liver Transplantation Database Group. JAMA 1999;281:1381.Showstack J., Katz P.P., Lake J.R. et al. Resource utilization in liver transplantation: offects of patient characteristics and clinical practice. NIDDK Liver Transplantation Database Group. JAMA 1999;281:1381.Talwalkar J.A., Seaberg E., Kim W.R. et al. Predicting clinical and economic outcomes after liver transplantation using the Mayo primary sclerosing cholangitis model and ChildPugh score. Liver Transplant 2000:6:753—8.Talwalkar J.A., Seaberg E., Kim W.R. et al. Predicting clinical and economic outcomes after liver transplantation using the Mayo primary sclerosing cholangitis model and ChildPugh score. Liver Transplant 2000:6:753—8.Schnitzler M.A., Woodward K.S., Brennan D.C. et al. The economic impact of preservation time in cadaveric liver transplantation. Am J Transplant 2001;1:360.Schnitzler M.A., Woodward K.S., Brennan D.C. et al. The economic impact of preservation time in cadaveric liver transplantation. Am J Transplant 2001;1:360.Reilly J., Mehta R., Teperman L. et al. Nutritional support after liver transplant: A randomised prospective study. JPEN 1990;14:386—91.Reilly J., Mehta R., Teperman L. et al. Nutritional support after liver transplant: A randomised prospective study. JPEN 1990;14:386—91.Keeffe E.B. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? Am J Gastroenterol 1995;90:201—5.Keeffe E.B. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? Am J Gastroenterol 1995;90:201—5.Vento S., Garofano T., Renzini C. et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. New Engl J Med 1998;338:286—90.Vento S., Garofano T., Renzini C. et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. New Engl J Med 1998;338:286—90.Lucey M.R., Brown K.A., Everson G.T. et al. Minimal criteria for placement of adults on the liver transplant waiting list: A report of a national conference organized by the American Association for the Study of Liver Diseases. Liver Transplаnt Surgery 1997;3:628—37.Lucey M.R., Brown K.A., Everson G.T. et al. Minimal criteria for placement of adults on the liver transplant waiting list: A report of a national conference organized by the American Association for the Study of Liver Diseases. Liver Transplаnt Surgery 1997;3:628—37.Fattovich G., Giustina G., Degos F. et al. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463—72.Fattovich G., Giustina G., Degos F. et al. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463—72.Serfaty L., Aumaitre H., Chazouilleres O. et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998;27:1435—40.Serfaty L., Aumaitre H., Chazouilleres O. et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998;27:1435—40.Kruger M., Tillmann H., Trautwein C. et al. Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: A pilot study. Liver Transplаnt Surgery 1996;2:253.Kruger M., Tillmann H., Trautwein C. et al. Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: A pilot study. Liver Transplаnt Surgery 1996;2:253.Perrillo R., Rakela J., Martin P. et al. Lamivudine for suppression and/or prevention of hepatitis B when given pre/post transplantation. Hepatology 1997;26:260A.Perrillo R., Rakela J., Martin P. et al. Lamivudine for suppression and/or prevention of hepatitis B when given pre/post transplantation. Hepatology 1997;26:260A.Terrault N., Zhou S., Combs C. et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996;24:1327.Terrault N., Zhou S., Combs C. et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996;24:1327.O'Grady J., Smith H., Davies S. et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Hepatology 1992;14:104.O'Grady J., Smith H., Davies S. et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Hepatology 1992;14:104.Ottobrelli A., Marzano A., Smedile A. et al. Patterns of hepatitis delta virus reinfection and disease in liver transplantation. Gastroenterology 1991;101:1649—53.Ottobrelli A., Marzano A., Smedile A. et al. Patterns of hepatitis delta virus reinfection and disease in liver transplantation. Gastroenterology 1991;101:1649—53.Rizzetto M., Ponzetto A., Bonino F. et al. Superimposed hepatitis delta and the effect on viral replication in chronic hepatitis B. Hepatology 1991;3(suppl): 34—41.Rizzetto M., Ponzetto A., Bonino F. et al. Superimposed hepatitis delta and the effect on viral replication in chronic hepatitis B. Hepatology 1991;3(suppl): 34—41.Samuel D., Muller R., Alexander G. et al. Liver transplantation in European patients with the hepatitis B surface antigen. New Engl J Med 1993;329:1842.Samuel D., Muller R., Alexander G. et al. Liver transplantation in European patients with the hepatitis B surface antigen. New Engl J Med 1993;329:1842.Feray C., Gigou M., Samuel D. et al. Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation. Ann Inter Med 1998;128:810.Feray C., Gigou M., Samuel D. et al. Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation. Ann Inter Med 1998;128:810.Gane E.J., Portmann B.C., Naoumov N.V. et al. Long-term outcome of hepatitis C infection after liver transplantation. New Engl J Med 1996;334:815—20.Gane E.J., Portmann B.C., Naoumov N.V. et al. Long-term outcome of hepatitis C infection after liver transplantation. New Engl J Med 1996;334:815—20.Fukumoto T., Berg T., Ku Y. et al. Viral dynamics of hepatitis C early after orthotopic liver transplantation: Evidence for rapid turnover of serum virions. Hepatology 1996;24:1351—4.Fukumoto T., Berg T., Ku Y. et al. Viral dynamics of hepatitis C early after orthotopic liver transplantation: Evidence for rapid turnover of serum virions. Hepatology 1996;24:1351—4.Berenguer M., Ferrell L., Watson J. et al. Fibrosis progression in recurrent hepatitis C virus (HCV) disease: Differences between the U.S. and Europe [abstract]. Hepatology1998;28:220A.Berenguer M., Ferrell L., Watson J. et al. Fibrosis progression in recurrent hepatitis C virus (HCV) disease: Differences between the U.S. and Europe [abstract]. Hepatology1998;28:220A.Charlton M., Seaberg E., Wiesner R. et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998;28:823—30.Charlton M., Seaberg E., Wiesner R. et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998;28:823—30.Feray C., Samuel D., Gigou M. et al. An open trial of interferon alfa recombinant for C after liver transplantation hepatitis: Antiviral effects and risk of rejection. Hepatology 1999;22:1084—9.Feray C., Samuel D., Gigou M. et al. An open trial of interferon alfa recombinant for C after liver transplantation hepatitis: Antiviral effects and risk of rejection. Hepatology 1999;22:1084—9.Mazzaferro V. et al. Liver transplantation for treatment of small hepatocellular. Carcinomas in patients with cirrhosis. New Engl J Med 1996;334:693—9.Mazzaferro V. et al. Liver transplantation for treatment of small hepatocellular. Carcinomas in patients with cirrhosis. New Engl J Med 1996;334:693—9.Llovet J., Bruix J., Fuster J. et al. Liver transplantation for small hepatocellular carcinoma: The tumor-node-metastasis classification does not have prognostic power. Hepatology 1998;27:1572.Llovet J., Bruix J., Fuster J. et al. Liver transplantation for small hepatocellular carcinoma: The tumor-node-metastasis classification does not have prognostic power. Hepatology 1998;27:1572.Mazzaferro V., Regalia E., Montalto F. et al. Risk of HBV reinfection after liver transplantation in HBsAg-positive cirrhosis. Primary hepatocellular carcinoma is not a predictor for HBV recurrence. Liver 1996;16:117—22.Mazzaferro V., Regalia E., Montalto F. et al. Risk of HBV reinfection after liver transplantation in HBsAg-positive cirrhosis. Primary hepatocellular carcinoma is not a predictor for HBV recurrence. Liver 1996;16:117—22.Carithers R.L. Jr. Liver transplantation. Liver Transplаnt Surgery 1999;6:122—35.Carithers R.L. Jr. Liver transplantation. Liver Transplаnt Surgery 1999;6:122—35.Lucey M.R., Brown K.A., Everson G.T. et al. Minimal criteria for placement of adults on the liver transplant waiting list: A report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transplant Surgery 1997;3:628—37.Lucey M.R., Brown K.A., Everson G.T. et al. Minimal criteria for placement of adults on the liver transplant waiting list: A report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transplant Surgery 1997;3:628—37.

The authors declare that there are no conflicts of interest present.